Abstract:Background: Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer, often associated with poor prognosis and resistance to treatment. The Epidermal Growth Factor Receptor (EGFR) remains a crucial target in therapy. Methods: An advanced computational workflow was used to identify and optimize EGFR inhibitors, integrating active site prediction (CB-Dock2), ligand generation (Lead3), virtual screening (AutoDock Vina), ADMET analysis (ADMETlab 2.0), and QSAR modeling. The QSAR model was validated to ensure predictive reliability. Results: Compound g18_mol18 demonstrated a binding affinity of -9.9 kcal/mol, significantly stronger than the standard compound (-7.381 kcal/mol) (p = 0.039). Interaction analysis showed that g18_mol18 formed multiple hydrogen bonds and hydrophobic contacts with key residues. Despite its strong binding affinity, ADMET analysis highlighted challenges such as poor intestinal absorption (HIA: 0.005) and potential hepatotoxicity. However, its low hERG inhibition (0.302 vs. 0.923) indicates a lower risk of cardiotoxicity, suggesting a favorable cardiac safety profile. Conclusion: The study identifies g18_mol18 as a potent EGFR inhibitor with significantly higher binding affinity and more extensive interactions than current treatments. Although it presents pharmacokinetic challenges, these findings underline its potential as a more effective and safer alternative for NSCLC treatment, warranting further experimental validation and optimization for clinical applications. Such developments could lead to durable therapeutic responses, addressing key resistance issues seen with current EGFR inhibitors.

Optimization of Potent, Efficacious, Selective and Blood-Brain Barrier Penetrating Inhibitors Targeting EGFR Exon20 Insertion Mutations

Discovery and Optimization of Potent, Efficacious and Selective Inhibitors Targeting EGFR Exon20 Insertion Mutations

Discovery of N-((3r,4r)-4-Fluoro-1-(6-((3-Methoxy-1-Methyl-1h-Pyrazol-4-Yl)Amino)-9-M Ethyl-9h-Purin-2-Yl)Pyrrolidine-3-Yl)Acrylamide (Pf-06747775) Through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic Egfr Mutants with Selectivity over Wild-Type Egfr

Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR

Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor

Discovery of 1-{(3R,4R)-3-[5-Chloro-2-(1-methyl-1H-pyrazol-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxymethyl]-4-methoxy-pyrrolidin-1-yl}propenone (PF-06459988), A Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.

Discovery of a Novel Mutant-Selective Epidermal Growth Factor Receptor Inhibitor Using in silico Enabled Drug Discovery Platform

Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors

Discovery and Structural Optimization of N5-Substituted 6,7-Dioxo-6,7-dihydropteridines As Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors Against L858R/T790M Resistance Mutation.

Design, Synthesis, Anti-Tumor Activity, and Molecular Modeling of Quinazoline and Pyrido[2,3-D]Pyrimidine Derivatives Targeting Epidermal Growth Factor Receptor

Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFR(T790M/C797S) Mutants

Structure-Guided Design of C4-alkyl-1,4-dihydro-2 H -pyrimido[4,5- d ][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors

In Silico Exploration of Novel EGFR Kinase Mutant-Selective Inhibitors Using a Hybrid Computational Approach

Design, Synthesis, and Biological Evaluation of Pyrimido[4,5- d]pyrimidine-2,4(1 H,3 H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.

Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders

Structural optimization and structure-activity relationships of N 2-(4-(4-methylpiperazin-1-yl)phenyl)- N 8-phenyl-9 H -purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations

Design, synthesis and biological evaluation of EGFR kinase inhibitors that spans the orthosteric and allosteric sites

Discovery of AZD4747, a Potent and Selective Inhibitor of Mutant GTPase KRASG12C with Demonstrable CNS Penetration

Design and Optimization of Novel EGFR Inhibitors for NSCLC: A Computational Approach to Overcome Resistance Mechanisms

Discovery and Optimization of Dibenzodiazepinones As Allosteric Mutant-Selective EGFR Inhibitors

Discovery and Optimization of 4-Anilinoquinazoline Derivatives Spanning ATP Binding Site and Allosteric Site As Effective EGFR-C797S Inhibitors